TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven grade II or III soft tissue sarcoma of one of following high-risk groups:~  * Grade II/III primary tumor with lesion size of at least 5 cm, deep, and extracompartmental (S1)~ * Local recurrence of primary tumor (S2)~ * Inadequate surgical excision of S1 or S2 (S3)~* Disease recurrence after prior surgery allowed~* The following histological types are eligible:~  * Malignant fibrous histiocytoma~ * Liposarcoma (round cell and pleomorphic)~ * Leiomyosarcoma~ * Fibrosarcoma~ * Rhabdomyosarcoma~ * Synovial sarcoma~ * Malignant paraganglioma~ * Neurofibrosarcoma (malignant schwannoma)~ * Extraskeletal Ewing's sarcoma~ * Extraskeletal osteosarcoma~ * Malignant peripheral neuroectodermal tumors~ * Mesenchymal chondrosarcoma~ * Angiosarcoma~ * Miscellaneous sarcoma~ * Unclassified sarcoma~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* 18 to 70~Performance status:~* WHO 0-2 OR~* Karnofsky 60-100%~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,500/mm\^3~* Platelet count at least 100,000/mm\^3~* No bleeding disorder~Hepatic:~* Bilirubin less than 1.25 times upper limit of normal~* No severe hepatic dysfunction~Renal:~* Creatinine clearance greater than 60 mL/min~* No chronic renal failure~Cardiovascular:~* No documented existing cardiac failure~* No manifest heart failure (New York Heart Association class III or IV)~* Left ventricular ejection fraction no more than 10% below institutional normal~Other:~* No other prior or concurrent malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix~* No other severe disease~* No severe cerebrovascular disease~* No extremely obese patients~* No prior metallic implants relevant to the regional hyperthermia field~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy (except to disease recurrence outside study irradiation field)~Surgery:~* See Disease Characteristics~* No prior mutilative surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chronic Constipation in Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic PD according to UK PDS Brain Bank Clinical Diagnostic Criteria.~* Chronic constipation according to Roma III criteria for chronic functional constipation lasting from at least 6 months.~* Absence of dementia.~* Patients who are able to understand and sign the informed consent for participation in the study~Exclusion Criteria:~* People who suffer from other comorbidities that could interfere with the results of the study according to the investigator.~* People who are not able to provide reliable answers to the questionnaire according to the opinion of the investigator.~* Inclusion in other clinical trials at the time of the visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): 6 week treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microbiota Restoration Therapy in HIV With Repeated Low-Dose Interventions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* On stable antiretroviral therapy with plasma HIV RNA \<20 copies/mL during at least 48 weeks.~* CD4/CD8 ratio \<1~Exclusion Criteria:~* Pregnancy~* Gastrointestinal diseases, including cirrhosis~* Active infections, including HCV~* EBV and/or CMV negative patients (donors are not screened for EBV/CMV).~* Planned used of chemotherapy or antibiotics~* Allergy to sodium chloride or glycerol (the former components are capsule ingredients Generally Recognized As Safe (GRAS)~* Current or planned use of antimicrobial agents (including prophylactic treatments against P. jiroveci) other than ART.~* Neutropenia \<500 cells/uL or CD4 counts \<350 cells/uL~* Patients unable to give informed consent~* Patients unable to comply with the protocol requirements~* Predicted death within time period of follow-up~* Any other condition for which the treating physician thinks the treatment may pose a health risk~* Dysphagia: oropharyngeal, esophageal, functional, neuromuscular (e.g. stroke, multiple sclerosis, ALS)~* History of aspiration~* History of gastroparesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- FMT (Type: EXPERIMENTAL): Fecal microbiota capsules (provided by Openbiome).~Dosage:~* Induction: 10 capsules (single dose)~* Maintenance: 5 capsules, weekly, during 7 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules (provided by Openbiome).~Dosage:~* Induction: 10 capsules (single dose)~* Maintenance: 5 capsules, weekly, during 7 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) of 17 to 40 kg/m2~* Subjects must have two comparable psoriatic lesions measuring between 9 and 100 cm2 and these target lesions must be similar in size to each other, and separated by at least 15 cm.~Exclusion Criteria:~* Subjects with lesions solely involving the palms of the hands or soles of the feet or intertriginous areas, the scalp or the face.~* Subjects with pustular psoriasis or erythroderma.~* Subjects currently on other topical agents or UVB therapy within 2 weeks of the first dose of study medication.~* Subjects receiving PUVA within 4 weeks of the first dose of study medication.~* Subjects receiving systemic retinoids, etanercept, adalimumab or efalizumab or oral immunosuppressives within 3 months prior to the first dose of study medication.~* Subjects receiving any other biological therapy (infliximab, alefacept, abatacept, etc) within 3 months of the first dose of study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A: INCB018424 Ruxolitinib 0.5% (Type: EXPERIMENTAL): INCB018424 Ruxolitinib 0.5% vs vehicle applied once daily for 28 days
- Cohort B: INCB018424 Ruxolitinib 1.0% (Type: EXPERIMENTAL): INCB018424 Ruxolitinib 1.0% vs vehicle applied once daily for 28 days
- Cohort C: INCB018424 Ruxolitinib 1.5% (Type: EXPERIMENTAL): INCB018424 Ruxolitinib 1.5% vs vehicle applied twice for 28 days
- Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene (Type: EXPERIMENTAL): INCB018424 up to 1.5% versus Dovonex® calcipotriene 0.005% cream applied BID for 28 days
- Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate (Type: EXPERIMENTAL): INCB018424 up to 1.5% versus Diprolene ® AF betamethasone dipropionate 0.05% cream applied twice a day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient volunteered to participate in the study, and signed the Informed Consent~2. Age 18-70 years old, male or female~3. Patients with CD20+ DLBCL (including PMBCL and tFL), FL and MCL, at least one measurable lesion (LDi≥ 1.5 cm)~4. r/r lymphoma patients who received prior CD19 CAR-T therapy~5. At least one week from last treatment (radiation, chemotherapy, mAb, etc) to apheresis~6. No immunosuppressive therapy was used within 1 week before C-CAR066 infusion~7. No mAb treatment within 2 weeks before C-CAR066 infusion~8. Adequate organ and bone marrow function~9. No contraindications of apheresis~10. Expected survival time \> 3 months~11. ECOG scores 0-1~Exclusion Criteria:~1. Have a history of allergy to cellular products~2. Patients with cardiac insufficiency classified as Class III or IV according to the New York Heart Association (NYHA) Heart Function Classification Standard~3. A history of craniocerebral trauma, consciousness disorder, epilepsy, cerebral ischemia or hemorrhagic cerebrovascular disease~4. Patients with active CNS involvement~5. Patients with autoimmune disease, immunodeficiency, or other treatment requiring immunosuppressor~6. Severe active infection (except simple urinary tract, bacterial pharyngitis), or currently receiving intravenous antibiotics. However, prophylactic antibiotics, antiviral and antifungal treatments are allowed~7. Live vaccination within 4 weeks before apheresis~8. HIV, HBV, HCV and TPPA / RPR infections, and HBV carriers~9. Have a history of alcoholism, drug addiction and mental illness~10. Non-sterile subjects had any of the following: a) being pregnant / lactating; or b) having a pregnancy plan during the trial; or c) having fertility without taking effective contraception~11. Patients with severe fludarabine or cyclophosphamide hypersensitivity~12. The patient has a history of other primary cancers, except for the following:~    1. Non-melanoma such as skin basal cell carcinoma cured by resection~   2. Cured carcinoma in situ such as cervical, bladder or breast cancer~13. The investigators believe that there are other circumstances that are not suitable for the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- C-CAR066 (Type: EXPERIMENTAL): Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* JRA by American College of Rheumatology (ACR) criteria - Active joints - Initiate etanercept alone, etanercept plus methotrexate or other DMARDs, methotrexate alone, or methotrexate with other DMARDs within 6 months of entry into Registry~* Polyarticular or systemic RA in 3 or more joints at start of treatment

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Methotrexate group (Type: None): Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient completed a previous qualifying Idenix-Sponsored trial with telbivudine~* Patient was not discontinued from previous Idenix-Sponsored study~Other protocol-defined inclusion criteria may apply~Exclusion Criteria:~* Patient is pregnant or breastfeeding~* Patient is co-infected with hepatitis C, hepatitis D or HIV~Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- telbivudine (Type: EXPERIMENTAL): telbivudine 600 mg p.o. daily for 104 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CV004-007 Thrombosis Chamber Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs and clinical laboratory determinations~* Body Mass Index (BMI) of 18 to 32 kg/m2 inclusive. BMI = weight (kg)/ \[height (m)\]2~* Females who are not of childbearing potential (i.e., who are post-menopausal or surgically sterile) and men ages 18 to 65, inclusive~* Azoospermic males and women who are not of child-bearing potential (i.e. are postmenopausal or surgically sterile; see section 3.3.3 for the definition of WOCBP) are exempt from contraceptive requirements. However, women must still undergo pregnancy testing as described in this section~Exclusion Criteria:~* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population~* Any condition that could affect drug absorption~* Other protocol-defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment A: BMS-986120 (Type: ACTIVE_COMPARATOR): BMS-986120 on specified days
- Treatment B: Aspirin and Clopidogrel (Type: ACTIVE_COMPARATOR): Aspirin and Clopidogrel on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years of age~* current diagnosis of primary body dysmorphic disorder (BDD), based on a clinical structured diagnostic interview~* currently living in the United States~Exclusion Criteria:~* Psychotropic medication changes within 2 months prior to enrollment (Participants taking psychotropic medication must have been on a stable dose for at least 2 months prior to enrollment and not change medication during study period)~* Past participation in 4+ sessions of cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)~* Current severe substance use disorder~* Lifetime bipolar disorder or psychosis~* Acute, active suicidal ideation as indicated by clinical judgment and/or a score \>2 on the suicidal ideation subscale of the Columbia-Suicide Severity Rating Scale (C-SSRS).~* Current severe comorbid major depression, as indicated by clinical judgment and/or a Quick Inventory of Depressive Symptomatology- Self Report (QIDS-SR) total score ≥ 21~* Concurrent psychological treatment~* Does not own a supported Smartphone with a data plan~* Lack of technology literacy that would interfere with ability to engage with smartphone treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD) (Type: EXPERIMENTAL): 12-week Smartphone-delivered CBT for BDD.
- 12 Week Waitlist Control (Type: OTHER): 12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy undergraduate students aged 16 to 25 years~* Sign the informed consent~* Provide ID~Exclusion Criteria:~* Axillary temperature \> 37.0 centigrade at the time of dosing~* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine~* Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain~* Autoimmune disease or immunodeficiency~* Congenital malformation, developmental disorders or serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders)~* Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws~* History or family history of convulsions, epilepsy, brain disease and psychiatric~* History of any blood products within 3 months~* Administration of any other investigational research agents within 30 days~* Administration of any live attenuated vaccine within 30 days~* Administration of subunit or inactivated vaccines within 14 days~* Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent~* anti-HBsAg positive~* anti-HAV positive~* Pregnancy test result is positive

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Inactivated HAV vaccine (Type: EXPERIMENTAL): Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with one-dose regimen.
- Live attenuated HAV vaccine (Type: ACTIVE_COMPARATOR): Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received live attenuated HAV vaccine containing 6.50 lgCCID50/vial with one-dose regimen.
- Two-dose inactivated HAV vaccine (Type: EXPERIMENTAL): Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with two-dose regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Reproductive-age women (age 18-45) with dysmenorrhea~* Average menstrual pain ≥ 5/10 (0=no pain and 10=the worst imaginable pain) on at least one day during menses or during withdrawal uterine bleeding from cyclic OCs without painkillers~* Menstrual pain in the region between the umbilicus and the perineum, above the level of the inguinal ligament~* Indication the participant has attempted to resolve pain by medical means (including NSAIDs and/or OCPs)~Exclusion Criteria:~* Presence of active pelvic or abdominal malignancies (primary or metastatic)~* Absence of regular menses (including current pregnancy, recent pregnancy, or active breast feeding)~* Active genitourinary infection in the last four weeks~* Unable to read or comprehend the informed consent in English~* Unwilling to complete study procedures~* Presence of hypertension or risk for developing hypertension~* Unwillingness to take naproxen and/or placebo~* Contradictions to taking naproxen (allergies, kidney disease, anemia, alcoholism, cardiovascular disease, stomach or intestinal ulcer or abnormal liver function)~* Formal urological diagnosis such as overactive bladder or bladder pain syndrome.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Primary Dysmenorrhea (Type: EXPERIMENTAL): We will look at the effects of naproxen 500mg use on pain starting just before and during menses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Lidocaine Administration Techniques

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients refered to the University of Chicago Medical Centers Procedure Service for a planned medical procedure requiring local injection of lidocaine.~Exclusion Criteria:~* Patient who lack decisional capacity to consent~* Patients who lack the ability to answer questions in english using pain scales

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lidocaine onto skin prior to lidocaine subcutaneous injection (Type: EXPERIMENTAL): 1-2ml of 1% lidocaine dripped onto the surface of the skin immediately prior to subcutaneous injection of 1% lidocaine.
- lidocaine subcutaneous injection alone (Type: ACTIVE_COMPARATOR): 1% lidocaine subcutaneous injection alone by standard approach

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete